Clinical trials located in

Rzeszów

Rzeszów city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Rzeszów, the largest city in southeastern Poland, serves as the capital of Podkarpackie Voivodeship. Founded in the 14th century, it boasts a rich history visible in its well-preserved Old Town, with the Rzeszów Castle and the 17th-century Lubomirski Summer Palace as highlights. The city is a vibrant educational center, home to several universities. Rzeszów also features an underground tourist route, a network of cellars and tunnels beneath the market square, showcasing its historical depth.

  • CT-EU-00117746

    Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • Exploring the safety and effectiveness of somapacitan for growth in children

    The study is focused on evaluating the safety and effectiveness of somapacitan, a new growth hormone treatment. This treatment, given once a week through an injection, aims to assist children who were born small for their gestational age or have been diagnosed with Turner syndrome, Noonan syndrome, or idiopathic short stature. Over a three-year period, the study will monitor for any adverse events or side effects, particularly observing how somapacitan impacts children with these specific  conditions. Participants will receive thorough training from the study team on administering the medication at home. This research is vital for potentially improving treatment and quality of life for children facing growth challenges, emphasizing participant safety and well-being throughout the study process.

    • Somapacitan
  • Study of the safety and effectiveness of garetosmab in patients with progressive fibrodysplasia ossificans

    This trial is examining a new drug called Garetosmab in adults who suffer from a condition called Fibrodysplasia Ossificans Progressiva or FOP. The main aim is to check if the drug is safe and useful for these patients. The researchers also want to understand what side effects might occur, how much of the drug is in the blood at different times, and if the body creates any fighters against this drug (which might make it less effective). Patients’ subjective experiences with symptoms, like painful swelling, will also be recorded. The participants on extended treatment will have special considerations. Measurements such as the condition of the major joints and lungs’ function tests will also be taken. The patient himself/herself will also be asked to describe how they think the treatment is affecting them.

    • Placebo
    • Garetosmab
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    • XXB750
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    • Telisotuzumab Vedotin
    • Docetaxel
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    • Zamaglutenase/TAK-062
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    • Teriflunomide
    • Remibrutinib
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    • Ruxolitinib
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    • Ustekinumab
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    • Mirikizumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Long-term study on ofatumumab effects in relapsing multiple sclerosis atients

    This study is being conducted to assess the safety of long-term usage of a drug called ofatumumab in patients with relapsing multiple sclerosis, a condition that can disrupt the nervous system. As part of the study, an investigation is being carried out to determine the ease of administration and the efficacy of the drug. Individuals who have previously participated in other studies involving ofatumumab for multiple sclerosis are eligible to enroll in this study. A sub-study is also being conducted to examine the impact of ofatumumab on the body’s response to specific vaccines and an antigen known as KLH. Antigens are substances capable of triggering the production of antibodies in the body. Progress will be assessed based on the annual frequency of disease relapses and changes in disability, using the EDSS scale. EDSS evaluates factors such as vision, brain function, and walking ability.

    • Tetanus toxoid (TT) containing vaccine (Td, Tdap)
    • 13-valent pneumococcal conjugate vaccine (13-PCV)
    • 23-valent pneumococcal polysaccharide vaccine (23-PPV)
    • Seasonal Quadrivalent influenza vaccine
    • Keyhole limpet hemocyanin (KLH) neo-antigen
    • Ofatumumab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    • JNJ-78934804 (guselkumab, golimumab)
    • Golimumab
    • Guselkumab
  • Long-term study on Mirikizumab for active ulcerative colitis

    The study aims to evaluate the effectiveness and safety of the drug mirikizumab in individuals with a severe form of Ulcerative Colitis (UC). This comprehensive study involves many patients across various medical centers. Health improvement will be assessed using a specialized scoring method (MMS). The study will also closely monitor for any adverse effects.

    • Mirikizumab
  • Understanding new medicine in moderate to severe ulcerative colitis or Crohn’s disease

    This is a study about a medicine called TEV-48574, used to treat serious bowel diseases called ulcerative colitis and Crohn’s disease. The main purpose of this study is to see how well the medicine works and how much of it should be given to patients, specifically, every 4 weeks. The study aims to test two different doses of TEV-48574 while assessing its safety and the ease with which patients can manage it. Additionally, the research aims to analyze the long-term reactions of the body to the medication. Each participant will be observed for up to 66 weeks, and the entire study is expected to span approximately 37 months. The success of the treatment will be gauged through various tests, including the Mayo score, which considers symptoms such as rectal bleeding, stool frequency, and inflammation within the gut.

    • TEV-48574
  • Studying povorcitinib safety and effects on nonsegmental vitiligo

    This trial studies the effectiveness and safety of povorcitinib for nonsegmental vitiligo. Participants will receive Povorcitinib or a placebo for 52 weeks. The study aims to see if Povorcitinib can significantly improve vitiligo symptoms on the face and body. It’s open to adults with a clinical diagnosis of nonsegmental vitiligo. Safety, side effects, and treatment efficacy are key focuses, aiming to advance vitiligo treatments and care.

    • povorcitinib
  • Examining the effectiveness of a new medicine for recent heart attack patients

    This trial is focused on a medicine called BI 765845, and it aims to determine its effectiveness for individuals who have experienced a heart attack. The objective is to assess the effectiveness of different quantities of the medicine when administered to these patients. Participation is limited to adults who have recently suffered a heart attack. During the study, some participants will receive the medicine, while others will be administered a placebo. The placebo lacks any medicinal properties. The likelihood of receiving the real medicine is four times greater than receiving the placebo. Over the next three months, participants will be requested to make multiple visits to the study site for heart health assessments. Any side effects will be documented and regularly monitored. The goal is to compare the results between the medicine and the placebo to determine which one is more effective.

    • BI 765845- new potential medication for ST segment-elevation myocardial infarction

See more clinical trials in other cities in Poland:

.